Skip to search formSkip to main contentSkip to account menu

gadoversetamide

Known as: (N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium, Gadoversetamida, gadoversetamide [Chemical/Ingredient] 
A paramagnetic extracellular magnetic resonance imaging (MRI) contrast agent that facilitates visualization of abnormal vascularity. When placed in a… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Contrast MediaOrganometallic Compounds
GADOVERSETAMIDE 0.5 mmol in 1 mL INTRAVENOUS INJECTION, SOLUTION [OPTIMARK]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists
Highly Cited
2015
Highly Cited
2015
Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic…
I n this landmark article by Robert et al, an animal model is presented for the T1 signal hyperintensity in the deep cerebellar… 
Review
2014
Review
2014
Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis
Abstract Nephrogenic systemic fibrosis (NSF) is a serious, sometimes fatal disease. Findings in recent years have shown that a… 
Review
2009
Review
2009
Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition
The biodistribution of approved gadolinium (Gd)‐based contrast agents (GBCAs) is reviewed. After intravenous injection GBCAs… 
Highly Cited
2008
Highly Cited
2008
Performance of Delayed-Enhancement Magnetic Resonance Imaging With Gadoversetamide Contrast for the Detection and Assessment of Myocardial Infarction: An International, Multicenter, Double-Blinded…
Background— The identification and assessment of myocardial infarction (MI) are important for therapeutic and prognostic purposes… 
Review
2008
Review
2008
Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Review
2008
Review
2008
Extracellular gadolinium contrast agents: differences in stability.
Highly Cited
2008
Highly Cited
2008
Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand
To investigate the role of excess ligand present in gadolinium (Gd) ‐based contrast agents in the development of nephrogenic… 
2008
2008
A Serial Dilution Study of Gadolinium-Based MR Imaging Contrast Agents
BACKGROUND AND PURPOSE: With the approval of gadobenate dimeglumine, higher relaxivity MR contrast agents were introduced into… 
Review
2006
Review
2006
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
Recently, it has been reported [1, 2] that a serious adverse reaction called nephrogenic systemic fibrosis (NSF) may occur after… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)